Related Experiment Video
Updated: Oct 8, 2025
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Triple negative breast cancer: any closer to cracking the code?
1University of California Los Angeles, Santa Monica, California, USA.
Purpose Of Review:
Triple negative breast cancer is the most aggressive subtype of breast cancer and has traditionally lacked targeted therapies leading to worse prognosis in most patients.
Recent Findings:
We will review new targeted therapies for triple negative breast cancer including immunotherapy, antibody-drug conjugates, and poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors.
Summary:
Immunotherapy is now a backbone of PD-L1 positive metastatic triple negative breast cancer in the front-line setting as well as part of neoadjuvant therapy for high risk localized triple negative breast cancer. PARP inhibitors and a new antibody-drug conjugate are additional new therapies that can be used to improve the outcome for localized and metastatic triple negative breast cancers. None of these treatments were available before the review period for this paper.
Insights
New targeted therapies offer hope for aggressive triple negative breast cancer. Immunotherapy, antibody-drug conjugates, and PARP inhibitors are improving outcomes for patients with this challenging cancer.
Area of Science:
- Oncology
- Medical Research
Background:
- Triple negative breast cancer (TNBC) is an aggressive subtype with limited targeted treatment options.
- TNBC historically has a worse prognosis compared to other breast cancer subtypes.
Purpose of the Study:
- To review novel targeted therapies for triple negative breast cancer.
- To highlight recent advancements in treating this aggressive cancer subtype.
Main Methods:
- Literature review of recent studies on TNBC treatments.
- Focus on immunotherapy, antibody-drug conjugates, and PARP inhibitors.
Main Results:
- Immunotherapy is a key treatment for PD-L1 positive metastatic TNBC and high-risk localized TNBC.
- PARP inhibitors and new antibody-drug conjugates offer improved outcomes for both localized and metastatic TNBC.
- These advanced therapies represent recent breakthroughs, not previously available.
Conclusions:
- Emerging targeted therapies are transforming TNBC treatment paradigms.
- These novel agents provide new hope and improved prognosis for TNBC patients.
- Continued research into targeted therapies is crucial for advancing breast cancer care.
